Faruqi and Faruqui, LLP Logo
Share this page

Auxilium Pharmaceuticals Inc. (AUXL)



AUXILIUM PHARMACEUTICALS INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auxilium Pharmaceuticals Inc. (AUXL) Over the Proposed Sale of the Company to Endo International PLC (ENDP)

October 13, 2014– Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Auxilium Pharmaceuticals Inc. (“Auxilium” or the “Company”) (Nasdaq: AUXL) for potential breaches of fiduciary duties in connection with the sale of the Company to Endo International Plc (“Endo”) for approximately $2.6 billion.  The Company’s stockholders may elect to receive a combination of $16.625 in cash plus 0.2440 Endo ordinary shares, $33.25 in cash, or 0.4880 Endo ordinary shares for each share of Auxilium stock they own.

The investigation focuses on whether Auxilium’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair sales process and whether and by how much this proposed transaction undervalues the Company to the detriment of Auxilium’s shareholders.

If you own common stock in Auxilium and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Request Information

Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.

  • Company:
    Auxilium Pharmaceuticals Inc. (AUXL)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

MergerInfo Request
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 10/13/2014

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.